Supplemental material
OncoImmunology
Volume 13, 2024 - Issue 1
Original research
LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma
Morten Nielsena National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
https://orcid.org/0000-0002-1250-4885View further author information
https://orcid.org/0000-0002-1250-4885View further author information, Tine Monberga National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmarkhttps://orcid.org/0000-0002-7217-2974View further author information
https://orcid.org/0000-0002-7217-2974View further author information, Vibeke Sundvoldb Lytix Biopharma, Oslo, Norwayhttps://orcid.org/0000-0002-1819-3889View further author information
https://orcid.org/0000-0002-1819-3889View further author information, Benedetta Albieria National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmarkhttps://orcid.org/0009-0008-3202-5452View further author information
https://orcid.org/0009-0008-3202-5452View further author information, , Michael Mørk Petersenc Department of Orthopedic Surgery, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmarkhttps://orcid.org/0000-0002-2324-6420View further author information
https://orcid.org/0000-0002-2324-6420View further author information, , Özcan Meta National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark;e Department of Health Technology, Technical University of Denmark, Lyngby, Denmarkhttps://orcid.org/0000-0002-3256-7592View further author information
https://orcid.org/0000-0002-3256-7592View further author information, , Trevor Clancyf NEC Oncoimmunity AS, Oslo, Norwayhttps://orcid.org/0000-0001-9896-0613View further author information
https://orcid.org/0000-0001-9896-0613View further author information, , Baldur Sveinbjornssonb Lytix Biopharma, Oslo, Norwayhttps://orcid.org/0000-0002-5499-9345View further author information
https://orcid.org/0000-0002-5499-9345View further author information, Øystein Rekdalb Lytix Biopharma, Oslo, Norwayhttps://orcid.org/0000-0001-5563-6709View further author information
https://orcid.org/0000-0001-5563-6709View further author information, & Inge Marie Svanea National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, DenmarkCorrespondence[email protected]
https://orcid.org/0000-0002-9451-6037View further author information
https://orcid.org/0000-0002-9451-6037View further author information show all